相关实验视频

Updated: Jul 5, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

595

氧化物对患有胰岛素瘤的猫的影响

Shiori Sato1, Koji Hori2, Gaku Tanabe3

  • 1Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo, Japan.

JFMS open reports
|January 25, 2024
PubMed
概括

当其他治疗方法失败时,Diazoxide在患有严重脏疾病的猫中有效地管理了胰岛素瘤. 这一案例突出了二氧化作为猫类胰岛素瘤的潜在新疗法,尽管仔细监测副作用至关重要.

关键词:
有不良影响的不良影响.氧化 (diazoxide) 是一种果糖氨基酸的含量是多少低血糖症 低血糖症胰岛素瘤是一种胰岛素.

更多相关视频

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.0K
Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing10:32

Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing

Published on: January 11, 2013

16.5K

相关概念视频

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
174
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204